Date: 2015-01-19
Type of information: Grant
Company: Theravectys (France)
Investors: BpiFrance (France)
Amount: €1.9 million
Funding type: grant
Planned used: The funds will be used for the optimization and the upscale of the production process of Theravectys\' lentiviral vectors as well as the conduct of regulatory preclinical studies of a therapeutic vaccine against Adult T-Cell Leukemia/Lymphoma virally-induced by HTLV-1.
Others: * On January 19, 2015, Theravectys, a French biotech company specialized in the development of a new generation of therapeutic vaccines and immunotherapies against major global infectious diseases and cancers, announced the grant of €1.9 million from Bpifrance in the form of a repayable advance as part of the Development of Innovation Assistance program (ADI).“ Through the support of our manufacturing activities, this €1.9 million contribution will put us in a better position to successfully conduct the preclinical and Phase I/II trials related to our first vaccine candidate in oncology and against an indication of particular interest for Japan” said Pascale Piel, the company’s Chief Financial Officer.
Therapeutic area: Cancer - Oncology - Infectious diseases
